NCT05371405 Machine Learning in Atrial Fibrillation
| NCT ID | NCT05371405 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2020-02-12 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2020-02-12 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atrial fibrillation is a serious public health issue that affects over 5 million Americans (Miyazaka, Circulation 2006) in whom it may cause skipped beats, dizziness, stroke and even death. Therapy for AF is currently suboptimal, in part because AF represents several disease states of which few have been delineated or used to successfully guide management. This study seeks to clarify this delineation of AF types using machine learning (ML).
Eligibility Criteria
Inclusion Criteria: * undergoing ablation at Stanford of (a) paroxysmal AF (self-terminates \< 7 days), or (b) persistent AF (requires cardioversion to terminate). * Per our clinical practice and guidelines (Calkins et al, Heart Rhythm 2012), patients will have failed or be intolerant of ≥ 1 anti-arrhythmic drug. Exclusion Criteria: * active coronary ischemia or decompensated heart failure * atrial or ventricular clot on trans-esophageal echocardiography * pregnancy (to minimize fluoroscopic exposure) * inability or unwillingness to provide informed consent * rheumatic valve disease (results in a unique AF phenotype) * thrombotic disease or venous filters
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05371405 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, up to 80 Years, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05371405 currently recruiting?
Yes, NCT05371405 is actively recruiting participants. Contact the research team at sanjiv1@stanford.edu for enrollment information.
Where is the NCT05371405 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT05371405 clinical trial?
NCT05371405 is sponsored by Stanford University. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.